Overcoming Secondary Mutations of Type II Kinase Inhibitors.

Abstract excerpt

Type II kinase inhibitors bind in the "DFG-out" kinase conformation and are generally considered to be more potent and selective than type I inhibitors, which target a DFG-in conformation. Nine type II inhibitors are currently clinically approved, with more undergoing clinical development. Resistance-conferring secondary mutations emerged with the first series of type II inhibitors, most commonly at residues...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Mutation
• Share to Protein Kinase Inhibitors